Eagle Asset Management Inc decreased Coherent Inc (COHR) stake by 5.59% reported in 2016Q4 SEC filing. Eagle Asset Management Inc sold 90,260 shares as Coherent Inc (COHR)’s stock rose 22.14%. The Eagle Asset Management Inc holds 1.52M shares with $209.31 million value, down from 1.61M last quarter. Coherent Inc now has $5.06 billion valuation. The stock rose 0.15% or $0.31 reaching $205.92. About 143,663 shares traded. Coherent, Inc. (NASDAQ:COHR) has risen 87.98% since August 24, 2016 and is uptrending. It has outperformed by 79.12% the S&P500.
The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) hit a new 52-week high and has $75.10 target or 7.00% above today’s $70.19 share price. The 9 months bullish chart indicates low risk for the $2.64 billion company. The 1-year high was reported on Mar, 31 by Barchart.com. If the $75.10 price target is reached, the company will be worth $184.80 million more. About 452,034 shares traded. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 74.13% since August 24, 2016 and is uptrending. It has outperformed by 65.28% the S&P500.
Since October 3, 2016, it had 0 buys, and 15 sales for $11.51 million activity. FLATLEY JAY T sold 2,000 shares worth $388,000. The insider DiMarco Bret sold 1,244 shares worth $128,337. Sechrist Paul F also sold $794,406 worth of Coherent, Inc. (NASDAQ:COHR) on Wednesday, February 1. JAMES SUSAN M. had sold 3,500 shares worth $671,732 on Friday, February 17. SKAGGS STEPHEN A had sold 500 shares worth $99,065 on Monday, February 13. 519 shares valued at $100,520 were sold by SPINELLI LUIS on Friday, February 17. 26,781 shares were sold by AMBROSEO JOHN, worth $5.24 million on Monday, February 13.
Eagle Asset Management Inc increased Intercontinental Exchange In (NYSE:ICE) stake by 526,986 shares to 678,808 valued at $38.30 million in 2016Q4. It also upped Wageworks Inc (NYSE:WAGE) stake by 150,141 shares and now owns 359,540 shares. Smith (A.O.) Corp (NYSE:AOS) was raised too.
Among 5 analysts covering Coherent (NASDAQ:COHR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Coherent had 12 analyst reports since August 3, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Coherent, Inc. (NASDAQ:COHR) on Monday, March 7 with “Buy” rating. The company was maintained on Monday, May 23 by Benchmark. The stock of Coherent, Inc. (NASDAQ:COHR) earned “Buy” rating by Stifel Nicolaus on Friday, January 29. The firm has “Neutral” rating by Susquehanna given on Wednesday, February 15. The firm earned “Buy” rating on Wednesday, September 2 by TheStreet. The firm earned “Buy” rating on Monday, January 9 by Stifel Nicolaus. Needham maintained the stock with “Buy” rating in Thursday, November 3 report. Stifel Nicolaus maintained it with “Buy” rating and $145 target in Tuesday, January 3 report. The firm earned “Buy” rating on Thursday, November 10 by Benchmark. Needham maintained Coherent, Inc. (NASDAQ:COHR) rating on Friday, January 29. Needham has “Buy” rating and $85 target.
Investors sentiment decreased to 1.05 in Q4 2016. Its down 0.03, from 1.08 in 2016Q3. It is negative, as 21 investors sold COHR shares while 96 reduced holdings. 58 funds opened positions while 65 raised stakes. 22.39 million shares or 0.42% less from 22.48 million shares in 2016Q3 were reported. Principal Financial Group Inc Incorporated reported 0.03% in Coherent, Inc. (NASDAQ:COHR). Voloridge Mngmt Ltd Liability stated it has 0.05% of its portfolio in Coherent, Inc. (NASDAQ:COHR). The New York-based Gotham Asset Mgmt Lc has invested 0.01% in Coherent, Inc. (NASDAQ:COHR). Tributary Capital Mngmt Llc stated it has 85,599 shares. The Arizona-based Arizona State Retirement Systems has invested 0.03% in Coherent, Inc. (NASDAQ:COHR). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment holds 0% in Coherent, Inc. (NASDAQ:COHR) or 3,125 shares. Eagle Asset Management Incorporated has invested 1.38% of its portfolio in Coherent, Inc. (NASDAQ:COHR). California-based Aperio Gru Ltd Liability has invested 0.01% in Coherent, Inc. (NASDAQ:COHR). Stevens Cap Management Lp owns 3,563 shares or 0.02% of their US portfolio. Qs Investors Ltd Liability Corporation reported 4 shares. Riverhead Capital Mngmt Limited Company accumulated 1,200 shares or 0.01% of the stock. Columbia Pacific Ltd Com invested 0.66% of its portfolio in Coherent, Inc. (NASDAQ:COHR). 47,273 are owned by Citigroup. 10,287 are held by Nordea Invest Mngmt Ab. Northern Trust reported 342,053 shares.
Analysts await Coherent, Inc. (NASDAQ:COHR) to report earnings on April, 27. They expect $1.79 earnings per share, up 103.41% or $0.91 from last year’s $0.88 per share. COHR’s profit will be $43.99M for 28.76 P/E if the $1.79 EPS becomes a reality. After $2.24 actual earnings per share reported by Coherent, Inc. for the previous quarter, Wall Street now forecasts -20.09% negative EPS growth.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $2.64 billion. The Firm is engaged in developing and commercializing medicines to treat central nervous system disorders. It currently has negative earnings. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Among 10 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. SAGE Therapeutics had 14 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was downgraded by H.C. Wainwright to “Neutral” on Wednesday, February 22. The rating was upgraded by Chardan Capital Markets on Tuesday, February 14 to “Neutral”. Goldman Sachs initiated the shares of SAGE in report on Wednesday, March 30 with “Neutral” rating. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) earned “Buy” rating by Lake Street on Friday, March 11. On Wednesday, December 14 the stock rating was upgraded by Raymond James to “Strong Buy”. Stifel Nicolaus initiated it with “Buy” rating and $90 target in Monday, November 14 report. Chardan Capital Markets initiated SAGE Therapeutics Inc (NASDAQ:SAGE) on Tuesday, May 24 with “Sell” rating. H.C. Wainwright initiated it with “Buy” rating and $56 target in Thursday, June 23 report. JP Morgan maintained the stock with “Buy” rating in Thursday, September 3 report. The rating was initiated by BMO Capital Markets on Wednesday, June 29 with “Outperform”.
Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on May, 4. They expect $-1.56 EPS, down 60.82% or $0.59 from last year’s $-0.97 per share. After $-1.50 actual EPS reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts 4.00% negative EPS growth.
Since November 11, 2016, it had 0 insider buys, and 4 selling transactions for $1.37 million activity. Shares for $207,080 were sold by IGUCHI KIMI. 10,000 shares valued at $550,000 were sold by Anderson Thomas on Tuesday, November 15.
